Skip to main content

Oncology

1 drug is in development for Chronic Myeloid Leukemia.

Companies
1
Clinical trials
21
BioSniper AIPage evidence connected

Prepared research question

Which programs lead the Chronic Myeloid Leukemia pipeline—and what evidence could change the picture?

Run cited research

Traceable citations · Unknowns marked

Drug Pipeline by Phase

Phase 1(1)
DrugCompany
MGD024MACROGENICS INC (MGNX)
About this indication

Chronic Myeloid Leukemia context

Oncology·MeSH: Leukemia, Myelogenous, Chronic, BCR-ABL Positive (D015464)

Also known as: Chronic Granulocytic Leukemia, Chronic Granulocytic Leukemias, Chronic Myelocytic Leukemia, Chronic Myelocytic Leukemias, Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemias, Chronic Myeloid Leukemias, Leukemia, Granulocytic, Chronic, Leukemia, Myelocytic, Chronic, Leukemia, Myelogenous, Chronic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myelogenous, Ph1 Positive, Leukemia, Myeloid, Chronic, Leukemia, Myeloid, Ph1 Positive, Leukemia, Myeloid, Philadelphia Positive, Leukemia, Ph1-Positive Myelogenous, Leukemia, Ph1-Positive Myeloid, Leukemia, Philadelphia-Positive Myeloid, Leukemias, Ph1-Positive Myelogenous, Leukemias, Ph1-Positive Myeloid, Leukemias, Philadelphia-Positive Myeloid

Prevalence

12.0 / 100K

Incidence

1.9 / 100K/yr

Frequently asked questions

How many drugs are in development for Chronic Myeloid Leukemia?

BioSniper tracks 1 drug in development for Chronic Myeloid Leukemia across 1 company.

How many clinical trials target Chronic Myeloid Leukemia?

There are 21 clinical trials targeting Chronic Myeloid Leukemia tracked by BioSniper.

What is the prevalence of Chronic Myeloid Leukemia?

The estimated prevalence of Chronic Myeloid Leukemia is approximately 12.0 per 100,000 population.